SHR-A1811 (Not yet branded)

Other Medications

US Experimental EU Experimental ES Not available IV 4 Clinical Trials
HER2

Description

SHR-A1811 is an antibody-drug conjugate specifically designed to target HER2-expressing colorectal cancers. This therapy is used in patients with advanced colorectal cancer who have failed standard treatments including oxaliplatin and 5-fluorouracil-based regimens. The drug combines a HER2-targeting antibody with a cytotoxic payload to deliver chemotherapy directly to HER2-positive cancer cells.

Mechanism of Action

SHR-A1811 binds specifically to the HER2 receptor protein overexpressed on certain colorectal cancer cells. Upon binding, the conjugate is internalized by the cancer cell, where the cytotoxic payload is released to induce cell death while minimizing damage to normal cells that do not express HER2.

Molecular Targets

Side Effects

Fatigue Nausea Decreased appetite Diarrhea Neutropenia Anemia Peripheral neuropathy Infusion reactions

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07309770 Phase 2
Recruiting
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
China
NCT07676162 Phase 3
Not yet recruiting
A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer
China
NCT06199973 Phase 3
Active, not recruiting
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
China
NCT04513223 Phase 1
Archived
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
China

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
EU EMA StatusExperimental
ES Spain AccessNot available
AdministrationIV
Clinical Trials4
View Clinical Trials Back to Drug Glossary

Related Medications

Trastuzumab
Immunotherapy
55 trials
Trastuzumab deruxteca
Antibody-Drug Conjugate
14 trials
Trastuzumab Deruxtecan
Other Medications
14 trials
Tucatinib
Targeted Therapy
12 trials
Pertuzumab
Immunotherapy
11 trials
Lapatinib
Targeted Therapy
8 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.